4-1BB and CD28, 13.03

Adoptive T cell therapy, P09.01, P09.03

AI quantification, P12.07

allogeneic hematopoietic stem cell transplantation, P10.01

Allosteric, P01.09

AML, P12.02

anti-angiogenic antibodies, 10.02

anti-CD20 antibody, P06.03

antibodies, P01.10

Antigen-specific anti-tumor response, P09.03

Antisense oligonucleotide, P01.06

apoptosis, P02.09

avidity, P01.10

B cells, P06.02

B-Acute Lymphoblastic Leukemia, P02.05

BCG therapy, P03.01

binding kinetics, P01.10

bladder cancer, 03.06, P03.01

BMI, P10.01

BTLA, P02.01

Cancer-Testis Antigen, P09.04

CAR T cell therapy, P12.02

CAR T cell therapy of solid tumors, 10.01

CAR T-cells, 10.02, P09.06, P12.10

CAR-T cell, P09.02

Cbl-b, P01.03

CD22-targeted therapy, P12.08

CD47, 03.05

cell therapy, P09.05, P12.01

Cell-cell interaction, P12.03

Checkpoint blockade, 03.05

Chemoresistance, P01.01

Chimeric receptors, P12.05

compliance, P12.04

COVID-19, P01.02

CPP, P03.02

CRD1601, P01.08

CTCL, P06.02

Cytotoxic T cell, P12.03

Dendritic cells, P03.02

DLBCL, 10.03

drug accessibility, P12.08

Endocytosis, P05.02

epithelial ovarian cancer, P12.12

Exercise immunology, 09.03

fibroblasts, P04.04

flow cytometry, P02.09

Gastric cancer, P02.07, P04.03, P11.01

GDF-15, 03.04

Genomic variation, P02.06

GLP-compliant validation, P12.06

High-avidity TCR, P09.04

HLA-G, 03.05

HPK1, P01.08

HVEM, P02.01

ICI resistance, P01.06

imaging mass cytometry, P04.02

Immune checkpoint, P08.01

immune checkpoint inhibitor therapy, P12.11

Immune checkpoints, P01.07

Immune evasion, P01.07

Immune exclusion, 10.04

Immune Monitoring, P04.03

Immune response,, P01.02

Immune-related proteins, P02.08

immunity therapy, P02.06

Immunoassay, P12.05

immunometabolic risk assessment, P10.01

Immunometabolism, 10.04, P09.01

immunotherapy, 03.04, 03.06, P02.01, P02.05, P02.07, P05.02, P09.06, P12.02

In vivo dynamics, P12.10

Intravenous, P01.09

Intravital imaging, P06.03, P09.06

Isoliquiritigenin, P01.01

ketogenic diet, P05.01

LAG3, P08.01

linear discriminant analysis, P04.01

lung cancer, P09.05

macrophages, P04.04

MALT1, P06.01

Manetic targeting, P09.03

MDSC, 10.03

Medulloblastoma, P12.10

melanoma, P12.11

Metabolism, P05.02

MHC Class I HLA Complex, 13.05

MHCp specific, P09.07

Microbiotherapy, 03.06

Mouse FluoroSpot, P12.06

mouse model, P06.01

mRNA, 13.04, P03.02

Multiplex Immunofluorescence, P02.03

Natural Killer cells, P02.05

neoadjuvant therapy, P11.01

Neuroblastoma, P02.02, P04.02

Neuropilin-1, P01.06

NK, P02.09

NK Cells, P01.03

Non-small cell lung cancer, P04.01

organoids, P04.04

orthotopic renal cell carcinoma mouse model, 13.03

Ovarian cancer, P02.08

Pancreatic cancer, P01.02

paracaspase, P06.01

Patient derived organoids, P11.02

peripheral blood markers, P04.01

prostate cancer, P05.01

Protein-interaction, P12.05

Proximity ligation assay, P08.01

radiation, P12.01

RECQL4, P12.11

Recurrence, P02.08

resistance, 03.04

Rna co-detection, P02.10, P02.11, P02.12, P02.13, P02.14

RNAi, P01.03

Senescence, P11.02

single cell RNA-seq, P05.01

single-cell TCR sequencing, P12.09

Slc2a1/GLUT1, P09.01

Solid tumor, P02.10, P02.11, P02.12, P02.13, P02.14

Solid Tumors, P09.04, P12.09

Spatial Biology, P02.03, P02.10, P02.11, P02.12, P02.13, P02.14

Spatial Transcriptomics, 10.04

Spectral flow cytometry, P02.02

Splicing Factors, 13.05

STING, P01.09

superparamagnetic iron oxide nanoparticles, P09.02

surgical methods, P11.01

T cell differentiation, 13.03

T cell expansion, P09.07

T cell function, P12.07

T cells, 09.03, P01.07

T-cell exhaustion, P12.12

targeted transport, P09.02

TCR Therapy, 13.05

TCRtg, 13.04

TIL, P12.01

time-lapse, P12.07

TME, 10.03, P06.02, P12.12

TNFAIP3, P09.05

tumor immune microenvironment, P02.06, P02.07, P04.02

Tumor immunity, P01.01

Tumor microenvironment, P02.02, P12.03, P12.09

Tumor neoantigen vaccination, P12.06

vaccination, 13.04